| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 11/18/2010 | US20100292187 Methods for treating hepatitis c |
| 11/18/2010 | US20100292185 Beta-lactamase inhibitors |
| 11/18/2010 | US20100292181 Compositions and methods for detecting and treating hiv infections |
| 11/18/2010 | US20100292179 Target |
| 11/18/2010 | US20100292148 Targeted polylysine dendrimer therapeutic agent |
| 11/18/2010 | US20100292138 Peptide Derived from Hepatitis C Virus |
| 11/18/2010 | US20100292137 Antibiotics and Methods For Producing Them |
| 11/18/2010 | US20100292136 Polymyxin derivatives and uses thereof |
| 11/18/2010 | US20100292135 INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS |
| 11/18/2010 | US20100292132 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 11/18/2010 | US20100291680 Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission |
| 11/18/2010 | US20100291628 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| 11/18/2010 | US20100291246 Anti-infection P-compound™ |
| 11/18/2010 | US20100291239 Mixture of citric flavonoids to improve ruminal fermentation |
| 11/18/2010 | US20100291220 Antibiotic formulation and method of treatment |
| 11/18/2010 | US20100291218 Immunomodulatory compositions, formulations, and methods for use thereof |
| 11/18/2010 | US20100291199 Compositions and Methods For The Treatment and Prevention of Disease |
| 11/18/2010 | US20100291192 Detoxification method for lipopolysaccharide (LPS) or lipid A of gram-negative bacteria |
| 11/18/2010 | US20100291191 Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
| 11/18/2010 | US20100291189 Method for producing a membrane protein |
| 11/18/2010 | US20100291184 Wound dressing with apertured cover sheet |
| 11/18/2010 | US20100291177 Prevention of staphylococcus biofilm formation |
| 11/18/2010 | US20100291169 Polyelectrolyte Complex for Imparting Antimicrobial Properties to a Substrate |
| 11/18/2010 | US20100291168 Antimicrobial formulations comprising a combination of a pyridine thiol and a bis-quinolinium salt |
| 11/18/2010 | US20100291160 Pharmaceutical system for trans-membrane delivery |
| 11/18/2010 | US20100291154 Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient |
| 11/18/2010 | US20100291153 Vaccines against bordetella pertussis based on lps glycosyltransferase mutants |
| 11/18/2010 | US20100291152 Chemically modified peptides with improved immunogenicity |
| 11/18/2010 | US20100291150 Pseudomonas exotoxin a cd4+ t-cell epitopes |
| 11/18/2010 | US20100291149 Attenuated listeria spp. and methods for using the same |
| 11/18/2010 | US20100291148 Shigella mutants in the functions pertaining to the processes of maturing and recycling peptidoglycans and their uses as immunogens |
| 11/18/2010 | US20100291147 Recombinant rsv antigens |
| 11/18/2010 | US20100291146 Method of eliciting an immune response against pandemic influenza virus |
| 11/18/2010 | US20100291143 Inhibition of HIV and SHIV Replication with Antisense Interleukin-4 |
| 11/18/2010 | US20100291142 Bacterial Artificial Chromosome Containing Feline Herpes Virus Type 1 Genome and Uses Thereof |
| 11/18/2010 | US20100291139 Recombinant mva virus and the use thereof |
| 11/18/2010 | US20100291138 Vaccine |
| 11/18/2010 | US20100291137 Method for refolding neisserial nspa protein |
| 11/18/2010 | US20100291134 Truncated hepatitis c virus ns5 domain and fusion proteins comprising same |
| 11/18/2010 | US20100291130 Cloned genome of infectious hepatitis c virus strain hc-tn and uses thereof |
| 11/18/2010 | US20100291129 Norovirus and sapovirus antigens |
| 11/18/2010 | US20100291128 Novel compositions and vaccines against influenza a and influenza b infections |
| 11/18/2010 | US20100291116 Microparticle comprising cross-linked polymer |
| 11/18/2010 | US20100291115 Pharmaceutical composition for the sublingual administration of vaccines, method for the preparation of the same and uses thereof |
| 11/18/2010 | US20100291109 Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| 11/18/2010 | US20100291104 Bordetella outer-membrane protein antigens and methods of making and using the same |
| 11/18/2010 | US20100291102 Therapeutic Agent |
| 11/18/2010 | US20100291101 New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof |
| 11/18/2010 | US20100291100 Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions |
| 11/18/2010 | US20100291093 Antibody-mediated disruption of quorum sensing in bacteria |
| 11/18/2010 | US20100291092 Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases |
| 11/18/2010 | US20100291084 Use of il-23 antagonists for treatment of infection |
| 11/18/2010 | US20100291082 Antigen presenting cell targeted anti-viral vaccines |
| 11/18/2010 | US20100291075 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies |
| 11/18/2010 | US20100291070 Type iii secretion system component protein pa1698 of pseudomonas aeruginosa |
| 11/18/2010 | US20100291066 Donor specific antibody libraries |
| 11/18/2010 | US20100291063 Protease inhibition |
| 11/18/2010 | US20100291061 Process for making oligopeptides |
| 11/18/2010 | US20100291037 Immunogenicity using a combination of dna and vaccinia virus vector vaccines |
| 11/18/2010 | US20100291036 Compositions and methods for modulating vascular endothelial growth factor c (vegf-c) expression |
| 11/18/2010 | US20100291035 Respiratory syncytial virus with a genomic deficiency complemented in trans |
| 11/18/2010 | US20100291034 Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
| 11/18/2010 | US20100291033 Albumin Fusion Proteins |
| 11/18/2010 | US20100291032 Compositions and methods for the identification of inhibitors of retroviral infection |
| 11/18/2010 | US20100291031 Bicyclic nucleosides and nucleotides as therapeutic agents |
| 11/18/2010 | US20100291027 Hyaluronic acid (ha) injection vehicle |
| 11/18/2010 | US20100291024 Methods and compositions for the treatment of proliferative and pathogenic diseases |
| 11/18/2010 | US20100291021 Aliphatic prodrug linker |
| 11/18/2010 | US20100291019 Methods of Using Ophthalmic Compositions Comprising Povidone-Iodine |
| 11/18/2010 | US20100290995 Radio-opaque compounds, compositions containing same and methods of their synthesis and use |
| 11/18/2010 | US20100290982 Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles |
| 11/18/2010 | DE202010012041U1 Zubereitung zur Nagelpflege Preparation for nail care |
| 11/18/2010 | CA2762036A1 Inhibitors of human immunodeficiency virus replication |
| 11/18/2010 | CA2761917A1 Method for detoxification of lipopolysaccharide (lps) or of lipid a of gram-negative bacteria |
| 11/18/2010 | CA2761916A1 Method for admixing the lipopolysaccharide (lps) of gram-negative bacteria |
| 11/18/2010 | CA2761876A1 Haloalkyl heteroaryl benzamide compounds |
| 11/18/2010 | CA2761845A1 Thiophene[3,4-c]pyrrole pde4 mediators |
| 11/18/2010 | CA2761756A1 Treatment of urinary tract infections with antibacterial aminoglycoside compounds |
| 11/18/2010 | CA2761710A1 Methods of treating or preventing influenza associated illness with oxidative reductive potential water solutions |
| 11/18/2010 | CA2761674A1 Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds |
| 11/18/2010 | CA2761650A1 Macrocyclic compounds as hepatitis c virus inhibitors |
| 11/18/2010 | CA2761628A1 New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity |
| 11/18/2010 | CA2761627A1 Sulphated hyaluronic acids as regulator agents of the cytokine activity |
| 11/18/2010 | CA2761602A1 Desfesoterodine in the form of a tartaric acid salt |
| 11/18/2010 | CA2761595A1 Polyketide compound |
| 11/18/2010 | CA2761573A1 Bifidobacterium longum ncc2705 (cncm i-2618) and immune disorders |
| 11/18/2010 | CA2761444A1 Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders |
| 11/18/2010 | CA2761258A1 Antiviral compounds |
| 11/18/2010 | CA2760205A1 Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| 11/18/2010 | CA2759500A1 Thieno [2,3-b]pyridine derivatives as viral replication inhibitors |
| 11/17/2010 | EP2251426A1 Mammalian-type glycosylation in plants |
| 11/17/2010 | EP2251424A1 Antigenic neisserial peptides |
| 11/17/2010 | EP2251419A1 Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142 |
| 11/17/2010 | EP2251344A1 Formulation of boronic acid compounds |
| 11/17/2010 | EP2251036A1 Chimeric flavivirus vaccines |
| 11/17/2010 | EP2251023A1 Anti-methicillin-resistant staphylococcus aureus agent and anti-vancomycin-resistant enterococcus agent |
| 11/17/2010 | EP2251015A1 Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
| 11/17/2010 | EP2250887A2 Use of non-antibacterial tetracycline analog CMT-1002 and formulations thereof for the treatment of bacterial exotoxins |
| 11/17/2010 | EP2250185A1 Novel lupane derivatives |
| 11/17/2010 | EP2250174A2 Macrocyclic serine protease inhibitors |